Severe oral lichen planus: remission and maintenance with vitamin A analogues.
Twenty-five patients with chronic oral lichen planus, usually of the atrophic-erosive type, were treated for 2 months with Etretinate 0.6 mg/kg b.w./day, followed for 4 months by Etretinate 0.3 mg/kg/day, or 0.1% Tretinoin in an adhesive base. Complete resolution or improvement was seen in 85% of the lesions after first treatment. The number of patients with oral soreness and pain was significantly reduced (p less than 0.001). During the second treatment, the improvement was maintained or even increased in about 70% of the patients, irrespective of the mode of treatment. Treatment was discontinued in one patient owing to moderately increased serum transaminase levels. The number of drug-related drop-outs was significantly lower than in a previous study utilizing an etretinate dose of about 1 mg/kg/day (p less than 0.05). Other adverse effects were minor and tolerable. Retinoids offer an effective mode of therapy for severe oral lichen planus.
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005050:Etretinate / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008010:Lichen Planus / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy*; D012008:Recurrence; D014212:Tretinoin / Q000008:administration & dosage / Q000627:therapeutic use*
D014212:Tretinoin; D005050:Etretinate